SCHEMBL2243353

SCHEMBL2243353

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C4CCC4)nn3-c3cccc(C)c3)c(F)c2)ccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.58
ABL1 P00519 4/20 0.58
BRAF P15056 4/20 0.58
KDR P35968 3/20 0.58
RIPK1 Q13546 2/20 0.58
RAF1 P04049 2/20 0.58
RET P07949 2/20 0.58
KIT P10721 2/20 0.58
BCR P11274 2/20 0.58
FGFR1 P11362 2/20 0.58
PDGFRA P16234 2/20 0.58
FLT1 P17948 2/20 0.58
EPHA1 P21709 2/20 0.58
TTK P33981 2/20 0.58
FLT4 P35916 2/20 0.58
FLT3 P36888 2/20 0.58
MAPKAPK2 P49137 2/20 0.58
CLK1 P49759 2/20 0.58
LIMK1 P53667 2/20 0.58
CDK17 Q00537 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2243233 0.99 MAPK14 (0.58) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2241060 0.93 MAPK14 (0.54) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2241103 0.91 BRAF (0.49) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2247616 0.91 MAPK14 (0.54) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2240921 0.90 ABL1 (0.58) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2242576 0.90 ABL1 (0.60) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2247857 0.90 MAPK14 (0.49) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2240618 0.90 ABL1 (0.58) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2243426 0.90 MAPK14 (0.62) MAPK14ABL1BRAFKDRRIPK1
SCHEMBL2243874 0.89 ABL1 (0.58) MAPK14ABL1BRAFKDRRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195110-A1 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC 2011-08-11 US claimed
EP-2044053-A2 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER Bayer Healthcare, LLC (US) 2009-04-08 EP claimed
WO-2007064872-A2 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC (US) 2007-06-07 WO claimed
US-20110195110-A1 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC 2011-08-11 US disclosed
US-20110195110-A1 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC 2011-08-11 US disclosed
US-20110195110-A1 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC 2011-08-11 US disclosed
WO-2007064872-A2 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER BAYER HEALTHCARE LLC (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195110-A1 UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER UMPS, SLC14A1, CPS1 MAPK14 3645/4885ABL1 3359/4885BRAF 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.